MRI衍生的内脏脂肪定量增强肥胖患者非酒精性脂肪性肝炎严重程度及纤维化的分层
这项回顾性单中心研究纳入138例接受肝活检和化学位移编码MRI(IDEAL-IQ)的肥胖患者(BMI≥30 kg/m²),评估MRI衍生内脏脂肪含量(VFC)对纤维化性NASH(Fibro-NASH)的分层诊断价值。Fibro-NASH患者的中位VFC显著低于无Fibro-NASH者(P<0.001),VFC是Fibro-NASH的独立预测因子(OR=0.51,95%CI 0.26-0.97)。VFC联合肌肉脂肪含量和天冬氨酸氨基转移酶的模型预测Fibro-NASH的AUC最高(0.89;95%CI 0.80-0.97),优于VFA模型和单独VFC模型(均P<0.05)。
要点
- 肥胖患者中,Fibro-NASH(NAS≥4且纤维化分期≥2)者的中位VFC显著低于无Fibro-NASH者(P<0.001)。
- MRI衍生VFC是Fibro-NASH的独立预测因子(OR=0.51,95%CI 0.26-0.97)。
- VFC+肌肉脂肪含量+AST联合模型预测Fibro-NASH的AUC=0.89(95%CI 0.80-0.97),优于VFA模型和单独VFC模型(均P<0.05)。
核心结论
- MRI衍生的VFC可能作为无创生物标志物用于评估肥胖患者NASH严重程度及向Fibro-NASH的进展,将其整合入临床实践可能改善风险分层并促进对晚期肝病的及时干预。
研究设计与样本
- 回顾性单中心研究,纳入2020年4月至2022年9月间接受肝活检和化学位移编码MRI(IDEAL-IQ)的138例肥胖患者(BMI≥30 kg/m²),以组织学定义的Fibro-NASH(NAS≥4且纤维化分期≥2)为参考标准。
关键影像表现/征象
- Fibro-NASH患者的中位VFC显著低于无Fibro-NASH者(P<0.001)。
诊断标准与关键数值
- Fibro-NASH的组织学定义为NAFLD活动度评分(NAS)≥4且纤维化分期≥2。
- VFC预测Fibro-NASH的OR=0.51(95%CI 0.26-0.97)。
- VFC+肌肉脂肪含量+AST联合模型预测Fibro-NASH的AUC=0.89(95%CI 0.80-0.97),优于VFA模型和单独VFC模型(均P<0.05)。
临床应用与阅片要点
- 作者认为,将MRI衍生VFC整合入临床实践可能增强风险分层并促进对晚期肝病的及时干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Visceral adiposity is a key factor in the development of nonalcoholic steatohepatitis (NASH), yet its quantitative relationship with fibrotic progression remains inadequately characterized. This study aimed to assess the diagnostic performance of MRI-derived visceral fat content (VFC) for stratifying NASH severity and fibrosis in obese individuals.
METHODS: In this retrospective, single-center study, 138 obese patients (body mass index ≥ 30 kg/m²) who underwent liver biopsy and chemical shift-encoded MRI (iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantitation (IDEAL-IQ)) between April 2020 and September 2022 were included. Fibrotic NASH (Fibro-NASH) was defined histologically as a NAFLD activity score (NAS) ≥ 4 and fibrosis stage ≥ 2. MRI-derived metrics, including VFC and visceral fat area (VFA), were compared between groups. Multivariable logistic regression and receiver operating characteristic (ROC) analyses were performed.
RESULTS: Patients with Fibro-NASH had significantly lower median VFC compared to those without Fibro-NASH (P < 0.001). VFC was identified as an independent predictor of Fibro-NASH (odds ratio (OR) = 0.51, 95% CI: 0.26-0.97). A model combining VFC, muscle fat content, and aspartate aminotransferase exhibited the highest predictive accuracy for Fibro-NASH (AUC = 0.89; 95% CI, 0.80-0.97), outperforming models using VFA and VFC alone (both P < 0.05).
CONCLUSION: MRI-derived VFC represents a promising, noninvasive biomarker for assessing NASH severity and its progression to Fibro-NASH in obesity. Integrating VFC into clinical practice may enhance risk stratification and facilitate timely interventions for advanced liver disease.
引用
- Yu X, Li YL, Feng YZ, et al. MRI-derived visceral adipose tissue quantification enhances stratification of nonalcoholic steatohepatitis severity and fibrosis in obesity. Abdom Radiol (NY). 2026. PMID: 41801376. doi:10.1007/s00261-026-05449-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。